Frontage Holdings Corp. (HK:1521)
:1521
Want to see HK:1521 full AI Analyst Report?
Top Page
Frontage Holdings Corp.
(1521)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$1.00
▼(-2.91% Downside)
Action:ReiteratedDate:11/15/25
The overall stock score of 43 reflects significant concerns in financial performance, with declining profitability and free cash flow as the primary drag. Technical indicators further weigh on the score with bearish trends, while a high P/E ratio suggests overvaluation. Investors should approach with caution until signs of financial recovery emerge.
Positive Factors
Cash Generation Ability
Strong cash generation supports operational stability, providing the company with flexibility to invest in growth opportunities and manage debt.
Negative Factors
Profitability Decline
A significant decline in net profit margin reflects challenges in cost management and pricing power, potentially affecting long-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation Ability
Strong cash generation supports operational stability, providing the company with flexibility to invest in growth opportunities and manage debt.
Read all positive factors
Frontage Holdings Corp. (1521) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.02B
Dividend YieldN/A
Average Volume (3M)468.13K
Price to Earnings (P/E)38.3
Beta (1Y)1.08
Revenue Growth0.61%
EPS Growth770.00%
CountryHK
Employees1,560
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,037,524,900
10 Day Avg. Volume431,000
30 Day Avg. Volume468,133
Financial Highlights & Ratios
PEG Ratio-6.36
Price to Book (P/B)1.39
Price to Sales (P/S)1.82
P/FCF Ratio31.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$270.49M
Frontage Holdings Corp. Business Overview & Revenue Model
Company Description
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such ...
How the Company Makes Money
Frontage Holdings Corp. generates revenue primarily through its contract research services, which include preclinical studies, clinical trial management, and bioanalytical testing. The company charges clients for the services rendered, typically t...
Frontage Holdings Corp. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
55
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 253.01M | 254.91M | 259.86M | 250.36M | 184.44M | 125.81M |
| Gross Profit | 70.28M | 69.81M | 78.39M | 89.19M | 66.70M | 41.48M |
| EBITDA | 39.00M | 35.37M | 45.02M | 54.10M | 42.56M | 23.20M |
| Net Income | 3.83M | 791.00K | 10.81M | 25.73M | 18.43M | 17.15M |
Balance Sheet | ||||||
| Total Assets | 544.27M | 553.59M | 571.87M | 550.59M | 475.84M | 382.71M |
| Cash, Cash Equivalents and Short-Term Investments | 33.66M | 44.09M | 54.60M | 90.52M | 148.71M | 214.54M |
| Total Debt | 137.70M | 154.37M | 145.10M | 118.19M | 57.85M | 40.62M |
| Total Liabilities | 202.83M | 219.32M | 226.72M | 214.75M | 152.76M | 93.84M |
| Stockholders Equity | 340.17M | 333.00M | 342.50M | 333.08M | 319.84M | 287.87M |
Cash Flow | ||||||
| Free Cash Flow | 67.32M | 14.75M | 18.59M | 14.78M | -5.83M | 17.08M |
| Operating Cash Flow | 54.77M | 40.64M | 39.74M | 62.44M | 44.55M | 31.65M |
| Investing Cash Flow | -30.18M | -41.48M | -87.63M | -147.91M | -107.44M | -25.89M |
| Financing Cash Flow | -36.26M | -10.22M | 12.91M | 30.66M | -5.54M | -2.91M |
Frontage Holdings Corp. Technical Analysis
Negative
1.03
Price Trends
1.08
Negative
1.05
Negative
1.18
Negative
Market Momentum
-0.02
Positive
44.79
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1521, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.08, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.79 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1521.
Frontage Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$44.97B | 34.57 | 25.67% | ― | 16.65% | 0.87% | |
56 Neutral | HK$30.15B | -6.48 | -12.75% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$41.62B | -18.01 | -14.44% | ― | 28.41% | 33.61% | |
43 Neutral | HK$2.02B | 38.28 | 1.98% | ― | 0.61% | 770.00% |
* Healthcare Sector Average
HK:1521
Frontage Holdings Corp.
1.01
-0.11
-9.82%
HK:1548
Genscript Biotech
13.61
2.47
22.17%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.08
9.32
55.61%
HK:2096
Simcere Pharmaceutical Group Limited
12.25
3.74
43.95%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
79.90
42.05
111.10%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.89
-4.05
-37.02%
Frontage Holdings Corp. Corporate Events
Frontage Shareholders Unanimously Approve Share Transfer Deal at EGM
Jan 7, 2026
Frontage Holdings Corporation announced that shareholders at its extraordinary general meeting on January 7, 2026, approved an ordinary resolution by poll related to a share transfer agreement involving its Shanghai laboratory subsidiary and count...
Frontage Holdings Schedules EGM to Approve Share Transfer Agreement
Dec 12, 2025
Frontage Holdings Corporation has announced an extraordinary general meeting scheduled for January 7, 2026, to discuss and approve a share transfer agreement involving its subsidiary, Frontage Laboratories (Shanghai) Co., Ltd., and other parties. ...
Frontage Holdings Delays Circular Dispatch for Major Transaction
Nov 20, 2025
Frontage Holdings Corporation, a company incorporated in the Cayman Islands, announced a delay in the dispatch of a circular related to a major and connected transaction involving a Share Transfer Agreement. The circular, which includes vital info...
Frontage Holdings Reports Significant Profit Growth in Q3 2025
Oct 28, 2025
Frontage Holdings Corporation announced its unaudited financial results for the third quarter of 2025, reporting a slight revenue increase to approximately US$191.4 million for the nine months ending September 30, 2025. The company’s net pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.